Viking Therapeutics (VKTX): next trial readout expected around 2027-07-01
$VKTX · Viking Therapeutics, Inc.Trials that could report in the next 12 months: 2BiopharmaCTG
Catalyst timeline
Dates are estimated from each trial's registered completion date — none are FDA decision dates. Counts trials that fit our shared poll budget, not everything VKTX is running — see methodology.
- 2027-07-01in 45wVK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
- 2027-07-01in 45wVK2735 for Weight Management Phase 3
Pipeline
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Phase 3 | Active Not Recruitingenrolled, still running | 2027-07-01 | NCT07104383 |
| VK2735 for Weight Management Phase 3 | Phase 3 | Active Not Recruitingenrolled, still running | 2027-07-01 | NCT07104500 |
Status-change history
Every ClinicalTrials.gov change recorded for VKTX's trials — a running history no other tracker shows.
No status changes detected yet for this ticker.
Frequently asked
When is VKTX's next PDUFA date?
No disclosed PDUFA date is currently tracked for this ticker.
What phase is VKTX's lead program in?
Phase 3 — active not recruiting.
Where does this data come from?
ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.